Medpace (MEDP)
(Delayed Data from NSDQ)
$396.65 USD
-0.60 (-0.15%)
Updated May 21, 2024 04:00 PM ET
After-Market: $396.07 -0.58 (-0.15%) 6:22 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$396.65 USD
-0.60 (-0.15%)
Updated May 21, 2024 04:00 PM ET
After-Market: $396.07 -0.58 (-0.15%) 6:22 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum B VGM
Zacks News
Should You Add Universal Health (UHS) to Your Portfolio?
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on growing patient volumes at its acute care and behavioral healthcare facilities, acquisitions and a commendable financial stand.
Brookdale (BKD) February 2024 Weighted Average Occupancy Rises
by Zacks Equity Research
Brookdale (BKD) witnesses a continuous streak of 28 months of year-over-year improvements in the weighted average occupancy level.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Cigna (CI) Unveils Updated Long-Term Growth Targets & Solutions
by Zacks Equity Research
Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.
Community Health (CYH), Cost Plus Drugs Unite to Lower Drug Cost
by Zacks Equity Research
Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.
Zacks.com featured highlights Trip.com Group, Medpace, Centrus Energy and NVIDIA
by Zacks Equity Research
Trip.com Group, Medpace, Centrus Energy and NVIDIA have been highlighted in this Screen of The Week article.
Ensign Group (ENSG) Buys Nursing Units, Boosts U.S. Footprint
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado and one similar facility in Kansas to better serve the regions' patients and grow its healthcare portfolio.
4 Best Profitable Stocks to Invest in Using Net Income Ratio
by Tirthankar Chakraborty
Trip.com Group Limited (TCOM), Medpace (MEDP), Centrus Energy (LEU) and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace (MEDP) Is Up 0.64% in One Week: What You Should Know
by Zacks Equity Research
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
These 3 Buy-Rated Stocks Have Been Red-Hot
by Derek Lewis
While February is generally known to be a bit cold, these three stocks have been red-hot, rewarding investors considerably following strong quarterly results.
Zacks.com featured highlights Trip.com, Medpace, Centrus Energy, Suzano and NVIDIA
by Zacks Equity Research
Trip.com, Medpace, Centrus Energy, Suzano and NVIDIA have been highlighted in this Screen of The Week article.
5 Best Profitable Stocks to Buy Using Net Income Ratio
by Tirthankar Chakraborty
Trip.com Group Limited (TCOM), Medpace (MEDP), Centrus Energy (LEU), Suzano (SUZ) and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are You Looking for a Top Momentum Pick? Why Medpace (MEDP) is a Great Choice
by Zacks Equity Research
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
The Zacks Analyst Blog Highlights Medpace, Elevance Health and HealthEquity
by Zacks Equity Research
Medpace, Elevance Health and HealthEquity are part of the Zacks top Analyst Blog
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
3 Amazing Health Service Stocks to Brave "Labordemic" in 2024
by Urmimala Biswas
Here are the three stocks, MEDP, ELV and HQY, which have the potential to shield your portfolio from the impact of healthcare staffing challenges in 2024.
Tenet Healthcare (THC) Gains 60% in a Year: More Room to Run?
by Zacks Equity Research
Diversified treatment network, solid patient volumes in the Hospital segment and robust cash flows continue to drive Tenet Healthcare (THC).
Acadia Healthcare (ACHC) Opens Facility to Serve California
by Zacks Equity Research
Acadia Healthcare (ACHC) conducts a ribbon-cutting ceremony for its Indio-based acute care facility, which aims to cater to the dire need for high-quality behavioral healthcare services in the region.
Medpace Holdings, Inc. (MEDP) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.